Immunic clinical-stage biotechnology company focused on the discovery, development and commercialization of cell-based therapies capable of transforming the management of life-threatening conditions. Co.'s product candidate, the ELAD® System, is an investigational, extracorporeal human hepatic cell-based liver treatment designed to supplement hepatic function in order to improve survival rates among patients with acute forms of liver failure. In addition, Co. is also exploring the use of proteins produced by its VTL C3A cells to resuscitate donated livers prior to transplantation into patients as there is a need to increase the number and quality of livers available for transplant.

VTL — News

VTL — Price Chart